Celltrion posts record Q2 earnings on sales expansion

Celltrion announced, Monday, its earnings guidance for the second quarter of this year, projecting sales of 961.5 billion won ($691.28 million) and an operating profit of 242.5 billion won. The figures mark its strongest second-quarter performance. According to the guidance, the sales and operating profit each grew 9.9 percent and 234.5 percent year-on-year. The operating margin also improved to 25 percent. The biotech attributed the growth to strong global sales of its existing products and an improvement in its sales mix toward high-margin drugs. In particular, the sales of Remsima SC, Yuflyma, Vegzelma, Steqeyma and other high-margin products gained traction, boosting both revenue and operating profit. The company said high-margin products accounted for 53 percent of total sales, up from 30 percent a year earlier. Celltrion expects its growth momentum to be driven by high-margin products. In the second half of this year, the company plans to launch four new drugs — Omlyclo, Avtozma, Eydenzelt and Stoboclo-Osenvelt — in major markets, which is expected to accelerate its earnings grWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times